MiNK Therapeutics

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiNK Therapeutics reports positive Q4 results, eyes growth opportunities

MiNK Therapeutics demonstrated strong performance in Q4 2022, with positive Phase I results for agenT-797 and advancements in iNKT cell therapy.
While facing challenges in development timelines and financial stability, MiNK's unique mechanisms of action in cancer treatment position it well for future growth.
Opportunities lie in financing prospects, upcoming presentations, collaborations, and continued innovation in iNKT cell therapy for MiNK to capitalize on.

MiNK Therapeutics reports promising Q1 results, focuses on innovative cancer therapies

MiNK Therapeutics showcased promising clinical data on agenT-797 in solid tumor cancers, emphasizing its potential efficacy and safety profile.
The company's strategic focus on iNKT cell therapies and the MiNK-215 program highlights innovative approaches to addressing immune suppression mechanisms in tumors.
While facing challenges in dose optimization and program prioritization, MiNK Therapeutics has opportunities to further advance its pipeline and explore novel cancer treatment avenues.
Analyst inquiries into expansion studies and development strategies indicate a growing interest in MiNK's innovative therapies and potential for future growth.

MiNK Therapeutics reports promising Q3 results amidst financial challenges

MiNK Therapeutics showcased financial prudence and promising clinical outcomes with AgenT-797, while facing challenges in financial sustainability and treatment optimization.
The company's strengths lie in unique immune activation, diversified research programs, and the therapeutic potential of iNKT cells in challenging cancer environments.
Opportunities for MiNK Therapeutics include advancing clinical trials, exploring new treatment avenues, and leveraging partnerships for market expansion and therapeutic advancements.

MiNK Therapeutics advances iNKT cell programs with promising results

MiNK Therapeutics showcased progress in iNKT cell programs and promising results in gastric cancer trials.
Financially, the company ended the year with a cash balance of $3.4 million and reported a net loss of $22.5 million.
Analysts raised questions on enrollment, patient demand, financial strategies, and plans for engineered iNKT cell efforts.
Exploration of iNKT cells in new disorders and combination trials presents growth opportunities for MiNK Therapeutics.

MiNK Therapeutics reports progress in Q1 2024 earnings call

MiNK Therapeutics demonstrated progress in financials and program advancements in Q1 2024, with a focus on iNKT cell platform development.
While facing challenges in managing expenses and achieving profitability, the company's innovative therapies like MiNK-215 and agenT-797 show promise.
The ongoing trials and upcoming presentations offer opportunities for growth and partnerships, positioning MiNK Therapeutics for future success.

MiNK Therapeutics reports progress in iNKT cell therapy programs

MiNK Therapeutics (INKT) is making notable strides in advancing their iNKT cell therapy programs for various medical conditions, showcasing promising clinical results and strategic collaborations.
The company's commitment to innovation, diversification of their pipeline, and proactive approach to funding and partnerships position them well for future growth and success.
While facing regulatory and operational challenges, MiNK has opportunities to leverage their expertise and resources to drive therapy development, expand indications, and enhance treatment efficacy.

MiNK Therapeutics reports progress in iNKT therapy, financial stability

MiNK Therapeutics demonstrated strong performance in advancing their iNKT cell therapy platform and achieving positive clinical outcomes in Q3 2024.
The company's strengths include strategic additions to the Board of Directors, promising preclinical data, and a robust pipeline of potential therapies.
Challenges in trial management, defining endpoints, and financial sustainability need to be addressed, while opportunities exist in partnerships, market expansion, and operational optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday December 1st, at 4:45 PM ET.

MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) --  MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the presentation of new data from five presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q3 2022 Earnings Conference Call November 2, 2022 ET Company Participants Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Jack Allen - Baird Operator Good morning, and welcome to MiNK Therapeutics' Third Quarter 2022 Conference Call and Webcast.

MiNK Therapeutics, Inc. (INKT) Q3 2022 Earnings Call Transcript

-  Five presentations on clinical data and novel pipeline candidates at the Society of Cancer Immunotherapy (SITC) Meeting -  R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via webcast

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the company will host an in-person and virtual Research & Development Day on Thursday, November 10th, 2022 from 4:00-6:00 PM ET in Boston, MA, and via webcast.

MiNK Therapeutics to Host R&D Event November 10, 2022

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the acceptance of five abstracts for presentation at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting, to be held November 8 – 12th, 2022.

MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September:

MiNK Therapeutics to Participate at Upcoming Investor Conferences

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q2 2022 Earnings Conference Call August 9, 2022 11:00 AM ET Company Participants Kimberly Ha - Head of Investor Relations Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Kalpit Patel - B. Riley Securities Jack Allen - Baird Matthew Phipps - William Blair Operator Good day, and welcome to the MiNK Therapeutics Second Quarter 2022 Earnings Conference Call.

MiNK Therapeutics, Inc.'s (INKT) CEO Jennifer Buell on Q2, 2022 Results.

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the second quarter 2022 and provided a corporate update.

MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results

NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will attend the BTIG 2022 Biotechnology Conference. MiNK will participate virtually and host one-on-one meetings with investors on August 8th and 9th.

MiNK Therapeutics to Participate at BTIG Biotechnology Conference

Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ET Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ET

MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update

iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells.

MiNK Therapeutics A Bargain For Potential Cell Therapies

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the first quarter 2022 and provided a corporate business update.

MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its first quarter 2022 financial results and business update before the market opens on Tuesday, May 10, 2022.

MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update

NEW YORK, March 18, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, reported financial results for the fourth quarter and full year 2021.

MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its independent fourth quarter and full year 2021 financial results and a business update before the market opens on Friday, March 18, 2022.

MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that it has begun dosing patients with solid tumor cancers with AgenT-797 alone and in combination with approved anti-PD-1 checkpoint inhibitors in a Phase 1 open-label clinical trial.

MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27th, 2022, at 12:00 pm ET.

MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat hosted by Evercore on December 1st, 2021, at 8:25 AM ET.

MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced preliminary survival data from its phase 1 study of, agenT-797 (iNKT cell therapy) in intubated COVID-19 acute respiratory distress syndrome patients, and also presented new insights on its iNKT programs in cancer at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021).

MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the closing of its previously announced initial public offering of 3,333,334 shares of its common stock at a public offering price of $12.00 per share. All of the shares were offered by MiNK. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $40.0 million. The shares began trading on the Nasdaq Global Market on October 15, 2021 under the ticker symbol “INKT”.

MiNK Therapeutics Announces Closing of Initial Public Offering

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the pricing of its initial public offering of 3,333,334 shares of common stock at a public offering price of $12.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by MiNK, are expected to be approximately $40 million. The shares are expected to begin trading on the Nasdaq Global Market on October 15, 2021 under the ticker symbol “INKT.” The offering is expected to close on or about October 19, 2021, subject to the satisfaction of customary closing conditions. In addition, MiNK has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by MiNK.

News for MiNK Therapeutics Stock (INKT)